One lot of APO-Amitriptyline recalled due to a nitrosamine impurity
OTTAWA, ON, Feb. 7, 2023 /CNW/ - Apotex Inc. is recalling one lot of APO-Amitriptyline 10 mg tablets due to the presence of N-nitrosodimethylamine (NDMA), a nitrosamine impurity, above the acceptable limit. Patients should continue taking their amitriptyline drug, as the risks from not having adequate treatment outweigh possible effects of exposure to the levels of NDMA seen in the recalled product. Patients do not need to return their medication to the pharmacy.
NDMA is classified as a probable human carcinogen. This means that long-term exposure to a level above what is considered safe may increase the risk of cancer. Health Canada is advising that there is no immediate risk in continuing to take the recalled APO-Amitriptyline since the potential risk of cancer is with long-term exposure (every day for 70 years) to NDMA that exceeds safe levels.
Health Canada maintains a list of recalled amitriptyline drugs affected by this issue. Please see the full advisory for more information, including more on the risk and what patients should do.
Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide. Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead...
At the Summit on Clean Cooking in Africa, World Resources Institute (WRI) and the Clean Cooking Alliance (CCA) announced a strategic partnership to further embed clean cooking into a broad range of sustainable development initiatives across the two...
QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality...
FIRST QUARTER (JANUARY - MARCH 2024)
Oder intake SEK 238.5 M (206.6)Net sales SEK 257.2 M (230.2)Operating profit SEK 45.8 M (23.7)Profit after tax SEK 36.7 M (17.6)Earnings per share before/after dilution SEK 1.07 (0.51)Cash flow SEK 87.9 M...
In response to valuable feedback from our customers, Luraco Technologies is thrilled to announce the launch of an upgrade to our medical massage chair lineup. We are introducing the Luraco i9 Max Plus Series, a revolution of the i9 Max Series. The i9...
